• Mainly inhibits URAT1 (renal tubular urate transporter) and partly inhibits OAT4.
• Reduces reabsorption of uric acid in the kidneys, increases urinary uric acid excretion, and lowers serum uric acid levels.

• Treatment of hyperuricemia
• Management and prevention of gout (gouty arthritis, tophi)

• Taken orally; absorbed rapidly.
• Uric acid lowering starts soon after dosing; steady effect within several weeks.

• Higher risk of kidney stones / urinary calculi (due to increased urate excretion); encourage water intake.
• Not for acute gout flares (does not relieve joint pain; may prolong flare).
• Monitor renal function.
• Start low dose for titration.

Yichang Tianrui Biopharm Co., LTD. (Tianrui Biopharm), a wholly-owned subsidiary of Yichang Renfu Pharmaceutical Co., LTD., was established in November 2022, located in Baiyang Biological Industrial Park, Yichang High-tech Development Zone, Hubei Province.

Tianrui Biopharm with a total investment of about 3 million USD and a total land area of 22000㎡, design 13 GMP workshops, divided into three phases of construction. The company is mainly engaged in the research and development, production and sales of high-end APIs (including intermediates). At present, the first phase construction has been completed with an investment of about 120 million USD. There are 2 GMP commercial workshops with 9 production lines. With the main business of research, production, CMO and CDMO of high-end APIs, the company are committed to becoming a world-class high-end biopharmacetical API service provider.